{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:27:09Z","timestamp":1776936429770,"version":"3.51.4"},"reference-count":38,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of University and Research, PRIN 2022","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Italian Ministry of Health, IRCCS Ospedale Policlinico San Martino (Ricerca Corrente 2025)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Alleanza Contro il Cancro (ACC), Associazione per la Ricerca sui Tumori Rari AR3","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"liberal donations Wurth Italia (Luca Carozzi)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Italian Ministry of Health, IRCCS Ospedale Policlinico San Martino (5x1000)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Associazione Italiana per la Ricerca contro il Cancro (AIRC IG grant IG21570)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Associazione Italiana contro le leucemie-linfomi e mielomi (AIL)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Alleanza Contro il Cancro (ACC)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"CURIOSITY driven research funds (University of Genoa)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"liberal donations (Grazia Benvenuto e Piero Chiabra)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"donations from Rimorchiatori Riuniti","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Research Projects of National Interest (Italian Ministry of University and Research, ID:M4.C2.1.1)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]},{"name":"Italian Ministry of Health (5x1000 and Ricerca Corrente 2025)","award":["D53D23005000006"],"award-info":[{"award-number":["D53D23005000006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The ataxia\u2013telangiectasia-mutated (ATM) protein plays a crucial role in the DNA damage response, particularly in the homologous recombination (HR) pathway. This study aimed to assess the impact of deleterious ATM variants on homologous recombination deficiency (HRD) and response to PARP inhibitors (PARPi) in melanoma patients, using a cell line established from melanoma tissue of a patient carrying the c.5979_5983del germline ATM variant. Despite proven loss of heterozygosity, lack of ATM activation, and HRD, our model did not show sensitivity to PARPi. We assessed the potential contribution of the Schlafen family member 11 (SLFN11) helicase, whose expression is inversely correlated with PARPi sensitivity in other cancers, to the observed resistance. The ATM mutant cell line lacked SLFN11 expression and featured hypermethylation-mediated silencing of the SLFN11 promoter. While sensitive to the ATR inhibitor (ATRi), the addition of ATRi to PARPi was unable to overcome the resistance. Our findings suggest that ATM mutational status and HRD alone do not adequately account for variations in sensitivity to PARPi in our model. A comprehensive approach is essential for optimizing the exploitation of DNA repair defects and ultimately improving clinical outcomes for melanoma patients.<\/jats:p>","DOI":"10.3390\/ijms26157420","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:56:16Z","timestamp":1754409376000},"page":"7420","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-4279","authenticated-orcid":false,"given":"Eleonora","family":"Allavena","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy"},{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4683-4951","authenticated-orcid":false,"given":"Michela","family":"Croce","sequence":"additional","affiliation":[{"name":"Biotherapies, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1534-0521","authenticated-orcid":false,"given":"Bruna","family":"Dalmasso","sequence":"additional","affiliation":[{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8962-6487","authenticated-orcid":false,"given":"Cecilia","family":"Profumo","sequence":"additional","affiliation":[{"name":"Biotherapies, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Rigo","sequence":"additional","affiliation":[{"name":"Biotherapies, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-0832","authenticated-orcid":false,"given":"Virginia","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-4880","authenticated-orcid":false,"given":"Irene","family":"Vanni","sequence":"additional","affiliation":[{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-6261","authenticated-orcid":false,"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Campanini","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-0168","authenticated-orcid":false,"given":"William","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy"},{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-5281","authenticated-orcid":false,"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, Department of Surgical Sciences and Integrated Diagnostics, University of Genova, 16132 Genoa, Italy"},{"name":"Anatomic Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1708","authenticated-orcid":false,"given":"Gabriele","family":"Zoppoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy"},{"name":"Medicina Interna a Indirizzo Oncologico, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[{"name":"Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"},{"name":"Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3651-8173","authenticated-orcid":false,"given":"Paola","family":"Ghiorzo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy"},{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-8331","authenticated-orcid":false,"given":"Lorenza","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy"},{"name":"Cancer Genetics, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous Melanoma: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up\u2606","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217599","DOI":"10.1016\/j.canlet.2025.217599","article-title":"PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research","volume":"617","author":"Marranci","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chan, W.Y., Brown, L.J., Reid, L., and Joshua, A.M. (2021). PARP Inhibitors in Melanoma\u2014An Expanding Therapeutic Option?. Cancers, 13.","DOI":"10.3390\/cancers13184520"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2400658","DOI":"10.1200\/PO-24-00658","article-title":"Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations","volume":"9","author":"Kim","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jid.2021.01.024","article-title":"Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach","volume":"141","author":"Kim","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/2767-9764.CRC-23-0101","article-title":"PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo","volume":"3","author":"Niessner","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: Therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yajima, H., Lee, K.J., Zhang, S., Kobayashi, J., and Chen, B.P.C. (2009). DNA Double Strand Break Formation upon UV-Induced Replication Stress Activates ATM and DNA-PKcs Kinases. J. Mol. Biol., 385.","DOI":"10.1016\/j.jmb.2008.11.036"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Putti, S., Giovinazzo, A., Merolle, M., Falchetti, M.L., and Pellegrini, M. (2021). ATM Kinase Dead: From Ataxia Telangiectasia Syndrome to Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215498"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41436-021-01240-8","article-title":"Germline ATM Variants Predispose to Melanoma: A Joint Analysis across the GenoMEL and MelaNostrum Consortia","volume":"23","author":"Dalmasso","year":"2021","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/ng.959","article-title":"Genome-Wide Association Study Identifies Three New Melanoma Susceptibility Loci","volume":"43","author":"Barrett","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41588-020-0611-8","article-title":"Genome-Wide Association Meta-Analyses Combining Multiple Risk Phenotypes Provide Insights into the Genetic Architecture of Cutaneous Melanoma Susceptibility","volume":"52","author":"Landi","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pastorino, L., Dalmasso, B., Allavena, E., Vanni, I., Ugolini, F., Baroni, G., Croce, M., Guadagno, A., Cabiddu, F., and Andreotti, V. (2022). Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232416027"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM\u2013Chk2 and ATR\u2013Chk1 Pathways in DNA Damage Signaling and Cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12935-023-03144-w","article-title":"Modulation of SLFN11 Induces Changes in DNA Damage Response in Breast Cancer","volume":"23","author":"Raynaud","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-Wide DNA Methylation Analysis of Small Cell Lung Cancer Cell Lines Suggests Potential Chemotherapy Targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin. Epigenet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.6004\/jnccn.2022.7102","article-title":"Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity","volume":"21","author":"Zhou","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jonuscheit, S., Jost, T., Gajdo\u0161ov\u00e1, F., Wrobel, M., Hecht, M., Fietkau, R., and Distel, L. (2021). Parp Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. Genes, 12.","DOI":"10.3390\/genes12060849"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA Helicase Schlafen-11 (SLFN11) Sensitizes Cancer Cells to DNA-Damaging Agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR Inhibition Potentiates Genome Instability and Cell Death in ATM-Deficient Cancer Cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic Variations in Epithelial-to-Mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP Inhibitors and Cisplatin in Small Cell Lung Cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP Inhibitors by SLFN11 Inactivation Can Be Overcome by ATR Inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vanni, I., Pastorino, L., Tanda, E.T., Andreotti, V., Dalmasso, B., Solari, N., Mascherini, M., Cabiddu, F., Guadagno, A., and Coco, S. (2023). Whole-Exome Sequencing and CfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054302"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 Assay Feasible in Routine Tumor Samples Calls PARP Inhibitor Response beyond BRCA Mutation","volume":"10","author":"Cruz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","article-title":"Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4132\/KoreanJPathol.2014.48.5.351","article-title":"Preparation of Compact Agarose Cell Blocks from the Residues of Liquid-Based Cytology Samples","volume":"48","author":"Choi","year":"2014","journal-title":"Korean J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E2848","DOI":"10.1073\/pnas.1310677110","article-title":"Geminin Deploys Multiple Mechanisms to Regulate Cdt1 before Cell Division Thus Ensuring the Proper Execution of DNA Replication","volume":"110","author":"Ballabeni","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/09553002.2020.1711461","article-title":"Gamma Ray-Induced in Vitro Cell Migration via EGFR\/ERK\/Akt\/P38 Activation Is Prevented by Olaparib Pretreatment","volume":"96","author":"Chowdhury","year":"2020","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.18632\/oncotarget.2083","article-title":"Niraparib (MK-4827), a Novel Poly(ADP-Ribose) Polymerase Inhibitor, Radiosensitizes Human Lung and Breast Cancer Cells","volume":"5","author":"Bridges","year":"2014","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Amaro, A.A., Gangemi, R., Emionite, L., Castagnola, P., Filaci, G., Jager, M.J., Tanda, E.T., Spagnolo, F., Mascherini, M., and Pfeffer, U. (2023). Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15030886"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4251\/wjgo.v16.i5.2060","article-title":"Epigenetic Silencing Schlafen-11 Sensitizes Esophageal Cancer to ATM Inhibitor","volume":"16","author":"Zhou","year":"2024","journal-title":"World J. Gastrointest. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7420\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:20:39Z","timestamp":1760034039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":38,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26157420"],"URL":"https:\/\/doi.org\/10.3390\/ijms26157420","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}